Hypomethylating Agents | List of Frontiers open access articles

Original Research

Published on 12 Apr 2021

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

in T Cell Biology

Hussein A. Abbas
Patrick K. Reville
Xianli Jiang
Hui Yang
Alexandre Reuben
Jin Seon Im
Latasha Little
Jefferson C. Sinson
Ken Chen
Andrew Futreal

Frontiers in Immunology

doi 10.3389/fimmu.2021.659625

6,862 views
14 citations

Brief Research Report

Published on 02 May 2024

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

in Drugs Outcomes Research and Policies

Ludan Zhang
Rui Ge
Deng Pan
Pengjie Yue
Jingwen Zhang
Renjie Bian
Xiaojing Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1265840

3,735 views
3 citations

Systematic Review

Published on 30 Sep 2021

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches

in Hematologic Malignancies

Klaus Geissler

Frontiers in Oncology

doi 10.3389/fonc.2021.751668

7,752 views
8 citations

Review

Published on 28 Sep 2021

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

in Hematologic Malignancies

Guangjie Zhao
Qian Wang
Shuang Li
Xiaoqin Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.706030

9,856 views
25 citations

Review

Published on 25 Feb 2021

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

in Hematologic Malignancies

Kah Keng Wong
Rosline Hassan
Nik Soriani Yaacob

Frontiers in Oncology

doi 10.3389/fonc.2021.624742

13,631 views
45 citations

Original Research

Published on 23 Mar 2023

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

in Hematologic Malignancies

Zhangjie Chen
Sisi Zhen
Tingting Zhang
Yuyan Shen
Aiming Pang
Donglin Yang
Rongli Zhang
Qiaoling Ma
Yi He
Jialin Wei

Frontiers in Oncology

doi 10.3389/fonc.2023.1137175

5,419 views
11 citations

Review

Published on 23 Feb 2026

TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches

in Hematologic Malignancies

Shweta Deshpande
Wing Fai Li
Junmin Song
Mark Forsberg
Claudio Cerchione
Giovanni Martinelli
Marina Konopleva

Frontiers in Oncology

doi 10.3389/fonc.2026.1735418

1,307 views

Mini Review

Published on 13 Dec 2021

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

in Hematologic Malignancies

Konstantinos Liapis
Ioannis Kotsianidis

Frontiers in Oncology

doi 10.3389/fonc.2021.801524

13,090 views
12 citations

Case Report

Published on 19 Dec 2024

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

in Hematologic Malignancies

Yunshuo Xiao
Kun Yang
Qiuying Huang
Changqing Wei
Manlv Wei
Zhili Geng
Hui Wu
Tianhong Zhou
Xialoin Yin
Yali Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1477697

2,778 views
3 citations

Review

Published on 02 Nov 2020

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

in Hematologic Malignancies

Ahmad I. Antar
Zaher K. Otrock
Iman Abou Dalle
Jean El-Cheikh
Ali Bazarbachi

Frontiers in Oncology

doi 10.3389/fonc.2020.596134

11,472 views
18 citations

Review

Published on 02 Feb 2021

Maintenance Therapy in AML

in Hematologic Malignancies

Patrick K. Reville
Tapan M. Kadia

Frontiers in Oncology

doi 10.3389/fonc.2020.619085

23,184 views
30 citations

Mini Review

Published on 11 Aug 2016

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?

in Hematologic Malignancies

Garland Michael Upchurch
Staci L. Haney
Rene Opavsky

Frontiers in Oncology

doi 10.3389/fonc.2016.00182

8,031 views
16 citations

Case Report

Published on 28 Sep 2022

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report

in Hematologic Malignancies

Zhangbiao Long
Min Ruan
Wei Wu
Qingshu Zeng
Qingsheng Li
Zhengqi Huang

Frontiers in Oncology

doi 10.3389/fonc.2022.912696

4,499 views
6 citations

Original Research

Published on 21 Apr 2026

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients

in Hematologic Malignancies

Chen Cao
Minran Zhou
Xinwen Jiang
Qingli Ji
Xiaoqing Li
Sai Ma
Chunyan Chen

Frontiers in Oncology

doi 10.3389/fonc.2026.1826350

466 views

Original Research

Published on 14 Jul 2025

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study

in Pharmacology of Anti-Cancer Drugs

Ji-Xin Tian
Ping Zhang
Xiao-Xu Wang
Jin-Wen Li
Dong-Xue Liu
Yi-Ying Liu
Zhi-Jian Xiao
Wen-Juan Miao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586910

2,225 views

Original Research

Published on 15 Sep 2025

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

in Hematology

Jiaying Cheng
Haipeng Fu
Ling Jiang
Yun Huang
Yujiao Zhang
Zhiquan Long
Xuejie Jiang

Frontiers in Medicine

doi 10.3389/fmed.2025.1638176

3,072 views
1 citation

Articles

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT

TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Maintenance Therapy in AML

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report

A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation